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ABSTRACT
Host cell differentiation-dependent regulation of human papillomavirus (HPV) gene expression is required for productive infec-
tion. The host cell CCCTC-binding factor (CTCF) functions in genome-wide chromatin organization and gene regulation. We
have identified a conserved CTCF binding site in the E2 open reading frame of high-risk HPV types. Using organotypic raft cul-
tures of primary human keratinocytes containing high-risk HPV18 genomes, we show that CTCF recruitment to this conserved
site regulates viral gene expression in differentiating epithelia. Mutation of the CTCF binding site increases the expression of the
viral oncoproteins E6 and E7 and promotes host cell proliferation. Loss of CTCF binding results in a reduction of a specific alter-
natively spliced transcript expressed from the early gene region concomitant with an increase in the abundance of unspliced
early transcripts. We conclude that high-risk HPV types have evolved to recruit CTCF to the early gene region to control the bal-
ance and complexity of splicing events that regulate viral oncoprotein expression.
IMPORTANCE
The establishment andmaintenance of HPV infection in undifferentiated basal cells of the squamous epithelia requires the acti-
vation of a subset of viral genes, termed early genes. The differentiation of infected cells initiates the expression of the late viral
transcripts, allowing completion of the virus life cycle. This tightly controlled balance of differentiation-dependent viral gene
expression allows the virus to stimulate cellular proliferation to support viral genome replication with minimal activation of the
host immune response, promoting virus productivity. Alternative splicing of viral mRNAs further increases the complexity of
viral gene expression. In this study, we show that the essential host cell protein CTCF, which functions in genome-wide chroma-
tin organization and gene regulation, is recruited to the HPV genome and plays an essential role in the regulation of early viral
gene expression and transcript processing. These data highlight a novel virus-host interaction important for HPV pathogenicity.
Papillomaviruses are a highly diverse family of small DNA tu-mor viruses that specifically infect the mucosal and cutaneous
epithelium. Human papillomavirus (HPV) types that infect themu-
cosal epithelium are subdivided into low-risk and high-risk groups,
depending on their association with cancer development (1, 2).
Following infection of cells in the basal layer of epithelium, the
viral genome is amplified and maintained as a low-copy-number
episome (estimated to be between 10 and 200 copies per cell) (3).
RNA polymerase II-dependent transcription of the early proteins
is initiated from the early promoter located upstream of the E6
open reading frame (ORF) (P97 in HPV16 and P105 in HPV18 and
HPV31) within the viral upstream regulatory region (URR). This
drives expression of the E6 and E7 oncoproteins in the basal cells
and stimulates continued cellular proliferation. The E7 gene prod-
ucts target members of the retinoblastoma family of proteins,
pRb/p105 (4) and p107 (5), which control cell cycle entry in the
basal layer. E7 also targets pRb2/p130 (6), which is highly ex-
pressed in the upper layers of the epithelium and prevents cell
cycle reentry (7). To circumvent increased p53 expression and cell
cycle arrest arising from E7 expression, high-risk E6 protein binds
p53 and targets it for degradation (8). By promoting cell cycle
reentry and delaying differentiation, E6 and E7 facilitate virus rep-
lication in cells that normally would have exited the cell cycle. In
the upper epithelial layers, the viral genome copy number rises in
part as a result of increased production of the viral E1 and E2
proteins (9, 10). Increased E2 expression is thought to repress E6
and E7 production (11), stimulating cellular differentiation and
subsequent activation of the differentiation-dependent late pro-
moter (12). This allows the production of transcripts encoding
E1^E4, which promotes viral genome amplification (13), and the
L1 and L2 capsid proteins (14). This intricate balance and control
of early and late gene expression is essential for the completion of
the HPV life cycle.
All HPV transcripts are polycistronic. Alternative splicing and
polyadenylation of transcripts further regulate HPV early gene
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expression and increase the repertoire of expressed proteins (14–
17). Exactly how splicing of the early transcripts is regulated is not
clearly understood, but suboptimal configuration of the 3= splice
sites is thought to allow selection between alternative splice accep-
tor sites (14). HPV16 also upregulates splicing factors in differen-
tiating epithelium to support late transcript processing (18, 19),
highlighting the ability of HPV to manipulate the host environ-
ment to control gene expression and coordinate the differentia-
tion-dependent life cycle.
CCCTC-binding factor (CTCF) is a ubiquitous host architec-
tural protein that binds 10,000 to 50,000 sites within the human
genome (20). Dynamic, three-dimensional organization of the
human genome by CTCF controls numerous genomic processes,
including transcription, genetic imprinting, chromatin insula-
tion, and gene splicing (21–25). These functions are coordinated
by CTCF through its ability to form long-range interactions,
bringing together distant regulatory elements to control gene ex-
pression (26), or by forming a roadblock which slows the tran-
scription machinery and alters cotranscriptional RNA splicing
(21). Due to the highly complex and regulated nature ofHPVgene
expression and posttranscriptional processing, we hypothesized
that CTCF regulates differentiation-dependent HPV gene expres-
sion.
MATERIALS AND METHODS
Bioinformatics. The DNA sequences for each HPV type screened are
defined in Table 2. Predictions for CTCF binding sites were made with a
combination of CTCF binding site databases (http://insulatordb.uthsc
.edu/ and http://bsproteomics.essex.ac.uk:8080/bioinformatics/ctcfbind
.htm) or using Storm analysis software. The position weight matrices
(PWM) utilized by these analysis tools have been published previously
(27–29).
Plasmids and antibodies. pUC19-HPV6b, pBR322-HPV11, and
pBR322-HPV16 were a gift from E.-M. de Villiers, DKFZ, Germany.
pBR322-HPV31 was a gift from L. Laimins, Northwestern University,
USA. pGEMII-HPV18 was a gift from F. Stubenrauch, University of
Tübingen, Germany, and was used as a template for site-directed mu-
tagenesis (QuikChange II XL; Agilent Technologies, USA) to create
pGEMII-HPV18-CTCF that contains three conservative nucleotide
substitutions (C2993¡T, G3005¡A, T3020¡C) within the E2 coding re-
gion. The plasmid pDrive-SP6-His-CTCF was a gift fromD. Farrar (Uni-
versity of Essex, United Kingdom) and encodes human CTCF protein
with a 10 histidine tag at the N terminus.
CTCF antibody was purchased from Active Motif (Belgium). FLAG
M2 and anti-cytokeratin 1/10 8.60 antibodies were purchased from Sig-
ma-Aldrich (United Kingdom). Anti-cytokeratin 5 D5/16 B4 was pur-
chased from Boehringer Mannheim Biochemica (Switzerland), and lori-
crin AF62 was from Covance Research Products (United Kingdom).
Bromodeoxyuridine (BrdU) and p130were purchased fromBectonDick-
inson (United Kingdom). Cyclin B1 H-433, HPV18 E6 (G-7), p53 DO1,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were pur-
chased from Santa Cruz Biotechnology (USA). Phospho-histone H3 (P-
H3; S10) was purchased from Cell Signaling (USA), and HPV18 E7 (8E2)
was fromAbcam (UnitedKingdom). All fluorescent secondary antibodies
were purchased from Invitrogen (United Kingdom). Rabbit polyclonal
anti-HPV16 E2 antibody was obtained from F. Thierry (Singapore) (9).
Monoclonal anti-E1^E4 1D11 (30) and rabbit polyclonal anti-E1^E4
r424 (31) were used to detect HPV18 E1^E4.
EMSA. For electrophoretic mobility shift assay (EMSA), DNA frag-
mentswere amplifiedwith a forward primer containing anM13-overhang
(sequences are available upon request) using master mix S (PeqLab, Ger-
many). The products of the first PCR thenwere amplified in a second PCR
using a 6-carboxyfluorescein (FAM)-labeled M13 forward primer. CTCF
protein was produced in an in vitro transcription translation reaction
using the TNT SP6 high-yield wheat germ protein expression system
(Promega, United Kingdom).
Two l of FAM-labeled DNA was incubated with 1 l CTCF protein
in a 10-l reaction mixture containing 0.5% NP-40, 50 mM KCl, 10 mM
Tris-HCl, pH 7.5, 0.1 g/l poly(dI-dC), 5% Ficoll 400, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 0.1 mMdithiothreitol (DTT). Sam-
ples were incubated at room temperature for 1 h before separation on a
4.5% native polyacrylamide gel. FAM fluorescence was imaged at 520 nm
using a Typhoon FLA7000 (GE Healthcare Life Sciences, United King-
dom).
ChIP. Chromatin immunoprecipitation (ChIP) assays were carried
out using the ChIP-IT express enzymatic ChIP kit (Active Motif) by fol-
lowing the manufacturer’s instructions. Cells were fixed in 1% formalde-
hyde for 3min at room temperature, andnuclei were released by 40 strokes
in a tight dounce homogenizer. DNA was purified using a GenElute PCR
cleanup kit (Sigma-Aldrich). ChIP efficiency was assessed by quantitative
PCR (qPCR) using SensiMix SYBR master mix (Bioline, London, United
Kingdom) using an MXPro 3000 (Agilent Technologies). Primer se-
quences used are available upon request. Cycle threshold (CT) values were
calculated at a constant threshold for each experiment, and the percentage
of input DNA was calculated using the standard curve.
Keratinocyte culture, transfection, and organotypic raft culture.
W12 cells containing episomal HPV16 genomes were cultured as previ-
ously described (32). The transfection of normal primary foreskin kerati-
nocytes (HFKs) from neonatal foreskin epithelia (ethical approval num-
ber 06/Q1702/45) was performed in S. Roberts’ laboratory by J. Parish as
previously described (31, 33). To eliminate donor-specific effects, 2 donor
lines were used: one produced as described above and one commercially
available HFK line (Clonetics, Lonza Group Ltd., Basel, Switzerland).
Emerging cell colonies were pooled and expanded as previously described
(34). Genomes were extracted from each line and sequenced to ensure
that the mutations were present in the mutant genome-containing lines.
Organotypic rafts were prepared (31) and cultured for 14 days in E me-
diumwithout epidermal growth factor to allow cellular stratification. Six-
teen hours prior to harvesting, 20 M BrdU was added to the growth
medium. Rafts then were fixed in 3.7% formaldehyde (Sigma-Aldrich)
and paraffin embedded prior to sectioning (Propath Ltd., Hereford,
United Kingdom).
Cell growth assay. A total of 1  105 terminally gamma-irradiated
J2-3T3 fibroblasts were seeded to each well of three 12-well tissue culture
microtiter plates and left to adhere. Wells then were seeded with 1 104
HFK lines in triplicate. The growth of cells was measured at days 1, 3, and
5 following removal of J2-3T3 fibroblasts by washing with EDTA and
phosphate-buffered saline (PBS). Five hundredl growthmediumand 50
TABLE 1 Primers used for HPV18 transcript analysis
Amplicon
Primer (5= to 3=)
Reference or
sourceForward Reverse
121-295 ATCCAACACGGCGACCCTAC GCAGCATGCGGTATACTGTCTCTA 14 and this study
121-3517 ATCCAACACGGCGACCCTAC ACGGACACGGTGCTGGAA 14
E1F1/E4R CAACAATGGCTGATCCAGAAG AGGTCCACAATGCTGCTTCT 15
CTCF Controls HPV Early Gene Expression
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TABLE 2 Prediction of CTCF binding in various HPV types and relative in vitro binding affinity
Class, type,a and
predicted motif
Fragment
tested Name Motif sequence
Confirmed
in vitro
Relative strength
of binding
High risk
HPV18 (AY262282.1)
843 754-943 18_1 ATTCCAGCAGCTGTTTCTGA No ND
1205 1102-1297 18_2 CCATTAGGGG No ND
2989 2926-3117 18_3 AAACCACCAGGTGGTGCCAG Yes Strongb
3487 3381-3575 18_4 CGGTGAGGGG No ND
3620 3527-3718 18_5 TTGCCTGTAGGTGTAGCTGC Yes Medium
4505 and 4537 4440-4638 18_6 and 18_7 CGTCCCCCAGTGGT/GTAACAATAGATGGGTCTGT Yes Two medium
bands
None 4947-5155 18_8 NA No ND
None 5045-5253 18_9 NA No ND
5473 5381-5577 18_10 CATACAGAGG Yes Medium
5767 5655-5850 18_11 CACCACCTGCAGGA Yes Medium
HPV16 (NC_001526.2)
1282 1216-1405 16_1 AACTCAGCAGATGTTACAGG No ND
2915 2852-3049 16_2 TAACCACCAAGTGGTGCCAA Yes Strongb
5118 5000-5207 16_3 CGCCTAGAGG Yes Weak
6127 6051-6278 16_4 CCTATAGGGG Yes Weak
6514 6426-6600 16_5 GAACCACTAGGTGTAGGAA Yes Weak
6859 6772-6957 16_6 CTCCCCCAGGAGGC Yes Weak
HPV31 (J04353.1)
615 534-713 31_1 ATAACAGTGGAGGTCAGTT No ND
885 804-1008 31_2 TGGGGAGGGG No ND
1093 1029-1200 31_3 CATGCAGAGG No ND
1277 1182-1374 31_4 AACGCAGCAGATGGTACAGG No ND
2332 2230-2406 31_5 CAACCACTGGCTGATGCTAA No ND
2412 2357-2531 31_6 AATGCACTAGATGGCAACC Yes Strongb
2853 2801-3015 31_7 TAACCACCAGGTGGTGCCAG Yes Strongb
None 2894-3093 31_8 NA No ND
5179 5077-5273 31_9 CCTTTAGGGG Yes Strong
6431 6354-6540 31_10 CTACACCTAGCGGC Yes Medium
Low risk
HPV6b (NC_001355.1)
1357 1251-1460 6b_1 CATACAGAGG No ND
None 2801-3007 6b_2 NA No ND
None 2887-3101 6b_3 NA No ND
4789 4715-4913 6b_4 TGTGCAGGGG No ND
5018, 4987 4913-5102 6b_5 and 6b_6 CTATCACTAGATGATACCA/CCTATAGAGG No ND
5424 5317-5515 6b_7 GCAGCCACAAGAGGGTGCAT Yes Strong
6109 5995-6199 6b_8 CAGCCATTAGGTGTGGGTGT No ND
6263 6179-6382 6b_9 CCCAAAGGGG Yes Medium
7205, 7256 7155-7380 6b_10 and 6b_11 CGAATAGAGG/CGTTTAGGGG No ND
HPV11 (FR872717.1)
1357 1295-1494 11_1 CATAGAGAGG No ND
None 2801-3003 11_2 NA No ND
None 2900-3104 11_3 NA No ND
4058 3930-4153 11_4 TGCAAAGGGG Yes Medium
4781 4709-4898 11_5 TGTGTAGGGG No ND
4920 4844-5041 11_6 CCACCTGTGGAGGCCAGTG Yes Weak
5415 5330-5501 11_7 GCAGCCACTAGAGGGTGCAG Yes Strong
6310 6243-6428 11_8 GTTCCAACGGGGGGCAGTC Yes Weak
6635 6544-6738 11_9 GAGCCACTAGGTGTATGTA Yes Weak, smear
6979 6872-7074 11_10 CCTCCACCAAATGGTACACT No ND
a The accession number of each HPV genome analyzed is indicated. The position in the viral genome of the first nucleotide of each predicted motif is given along with the specific
fragment tested by EMSA. Where a fragment was tested that did not contain a predicted motif, no position is given (none). Each fragment tested is named by HPV type followed by
the order of position in the genome starting at position 1 in the URR. The sequence of each motif is given (NA indicates that a motif was not predicted). Fragments were tested for
binding in vitro by EMSA. The relative strength of binding to each fragment was assessed qualitatively by comparison to the proportion of c-Myc-positive control DNA bound by
CTCF in the same assay (weak,50% binding; medium, 50 to 75% binding; strong,75% binding; ND, none detected). All EMSA experiments were repeated at least three times,
and the strength of binding reflects the relative binding strength achieved in all repeats.
b CTCF binding site within the E2 ORF that is conserved in all high-risk HPV types tested.
Paris et al.
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l CCK-8 reagent (DojindoMolecular Technologies, Inc.) were added to
eachwell, and the plate was incubated at 37°C for 2 to 4 h. Absorbancewas
read at 450 nm using an iMark microplate reader (Bio-Rad). Wells that
contained J2 3T3 fibroblasts but not HFK were used as a blank for each
plate.
Immunofluorescence. Four-m sections of organotypic cultures
were placed on polylysine-coated slides and incubated at 50°C for 30min.
One section from each raft was stained with hematoxylin and eosin for
morphological analysis. Antigens were retrieved using an agitated low-
temperature method, as previously described (35), following immersion
in Histoclear (National Diagnostics, Yorkshire, United Kingdom). Slides
were blocked with 20% heat-inactivated goat serum and 0.1% bovine
serum albumin (BSA) in PBS for 1 h at room temperature. Primary
antibodies were incubated on the slides overnight at 4°C. Incubation in
secondary antibody subsequently was performed at 37°C for 1 h. DNA
was stained with Hoechst 33342 before mounting in Fluoroshield
(Sigma-Aldrich). Microscopic analysis was performed in a Nikon E600
epifluorescence microscope, and images were captured using a Nikon
DXM1200F digital camera.
Chromogenic in situhybridization (C-ISH).Nuclei positive forHPV
DNAamplification in raft sectionswere detectedwith a biotin-conjugated
high-risk HPVDNA-specific probe using Leica Bond-Max technology, as
described by the manufacturer (Leica Microsystems, Milton Keynes,
United Kingdom).
Episome copy number determination. Southern blotting was per-
formed as described previously (36). For qPCR analysis, relative quanti-
ties of HPV18 genome in total DNA, amplified with primers 5=-TTATAG
GCGAGCCCAAAAAC-3= and 5=-CCAATCTCCCCCTTCATCTAT-3=,
were normalized against the TLR2 locus at chromosome 4q32 using the
Pfaffl comparative CT method (37).
Transcript analysis. RNA was extracted from 14-day-old HFK raft
cultures using RNA-STAT 60 (AMS Biotechnology Ltd., United King-
dom). Fiveg of RNA was treated with 1 U of RQ1 DNase (Promega) for
30 min at 37°C, which subsequently was inactivated for 10 min. Reverse
transcription was performed using a Tetro cDNA synthesis kit (Bioline).
Two l of cDNA was used for the amplification of HPV transcripts using
the primers listed in Table 1. Products were separated by electrophoresis,
and the relative intensity of each product was measured using ImageJ.
Statistical analysis.A two-tailed, unpaired student’s t test was used to
determine statistical significance.
RESULTS
Identification of CTCF binding sites in alpha-HPV genomes by
bioinformatic analysis. CTCF binding sites in the genomes of
low-riskHPV types 6b and 11 and high-riskHPV types 16, 18, and
31 were predicted using open access databases and Storm analysis
software (Table 2). These motif identification tools use a combi-
nation PWMpreviously described (27–29). As hypothesized, all of
the HPV types tested were predicted to bind CTCF at multiple
sites, although the number of predicted binding sites within dif-
ferent HPV types varied, ranging from six sites in HPV16 to 11
sites in HPV6b and HPV18. Numerous predicted binding sites
clustered within the late gene region of all types studied. An addi-
tional site was identified in the E2 open reading frame (ORF) that
was conserved in the high-risk but not in the low-risk viral types.
Verification of CTCF binding sites. To confirm our in silico
analysis, CTCF binding was assessed in vitro by EMSA. Approxi-
mately 200-bp DNA fragments containing the predicted binding
motifs were incubated with CTCF protein (Fig. 1A), and com-
plexes were separated by electrophoresis (Fig. 1B). A region of the
c-Myc promoter, previously shown to bind CTCF (38), and a
fragment of the BPV1 genome not predicted to bind CTCF were
included as controls. Fragments also were incubated with wheat
germ extract alone and in vitro-translated luciferase to control for
nonspecific binding of proteins. Fragments were tested a mini-
mum of three times, and the relative strength of binding com-
pared to that of the c-Myc positive-control DNA fragment was
estimated (Table 2 and Fig. 2).
The binding maps presented in Fig. 2 show conservation of
CTCF binding between HPV types. All types contain a cluster of
CTCF binding sites within the late gene region, ranging from 2
binding sites inHPV6b to 4 binding sites inHPV16. Furthermore,
the conservation of one to twoCTCFbinding sites within (or close
to) the E2ORFof the high-riskHPV typeswas confirmed. Binding
in this region was not detected in HPV6b or HPV11 with frag-
ments amplified from this region (Table 2). The conservation of
CTCF binding sites between HPV types supports our hypothesis
that CTCF recruitment is an important virus-host interaction in
the HPV life cycle.
CTCF associates with HPV16 and HPV18 genomes.We next
used HPV16 and HPV18 genome-containing cells to ascertain
whether CTCF associates with the viral genome in cells.W12 cells,
derived froma low-grade cervical squamous epithelial lesion, con-
tain 100 episomal HPV16 genome copies/cell (39, 40), and
HPV18-transfected HFKs contain200 episomal HPV18 copies/
cell (see Fig. 5B). CTCF association with the HPV genomes was
FIG 1 In vitro analysis of the association of CTCF with HPV genomes. (A)
Western blot analysis of in vitro-translated CTCF protein. Lysate from ID13
(mouse) cells known to express CTCF was loaded as a positive control along-
side wheat germ extract (WGE) andWGE used to translate luciferase (Luc) or
CTCF protein. A band running at approximately 140 kDa was present in the
ID13 cell lysate, and a slightly smaller band was present in the in vitro-trans-
lated CTCF reaction. Human CTCF is an 82-kDa protein but runs at approx-
imately 130 kDa on SDS-PAGE (71), whereas themouse homologue is slightly
larger. (B) An example of an EMSA of CTCF binding to predicted BPV DNA
fragments. DNA fragments were amplified and labeled with FAM by PCR.
Fragments were mixed with binding buffer only (DNA), in vitro-translated
luciferase protein (Luc) (), or in vitro-translated CTCF protein (	), and
protein-DNA complexes were separated on a native acrylamide gel. Free DNA
is indicated at the bottom of the gel and protein-DNA complexes near the top.
Each fragment was tested aminimumof three times, and the combined results
are shown in Table 2. Fragments from the c-Myc locus (positive control), a
region of the BPV-1 genome that is known not to bind CTCF (negative con-
trol), and fragment 11 from HPV18 and fragments 1 and 10 from HPV31 are
shown in the representative EMSA. 18_11 and 31_10 bound CTCF with me-
dium strength (50 to 75% binding compared to the c-Myc positive control),
and 31_1 did not bind CTCF in vitro.
CTCF Controls HPV Early Gene Expression
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determined by ChIP followed by qPCR. In both HPV16 and
HPV18 genome-containing cells grown in monolayer, we noted a
significant enrichment of CTCF binding within the E2 ORF, co-
inciding with the CTCF binding site conserved in high-risk HPV
types but not in low-risk types (Fig. 3). In contrast, we failed to
detect CTCF binding to the late gene region in either HPV16 or
HPV18 genome-containing model systems.
Loss of CTCF binding to the HPV18 genome does not alter
episome establishment or proliferation of primary human fore-
skin keratinocytes. To assess the biological function of CTCF
binding within the E2 ORF, mutations were introduced into the
HPV18 genome to prevent CTCF binding (Fig. 4A). Three nucle-
otide substitutions were introduced into the predicted binding
site that did not alter the amino acid coding sequence of E2
(CTCF HPV18). It should be noted that CTCF also has the po-
tential to bind to the cDNA strand within this region (at the se-
quence 5= CACCACCTGGTGGT 3=), although the mutations in-
troduced also would affect binding at this site. We observed a
near-complete loss of CTCF binding to the CTCF HPV18 se-
quence in EMSA, confirming that the mutations prevented CTCF
binding (Fig. 4B). HFKswere transfectedwith recircularizedwild-
type (WT) or CTCF HPV18 genomes, and immortalized lines
were established. To account for donor-specific effects, cells from
two independent donors were transfected, and all downstream
analyses were performed on both lines. No significant differences
in cellularmorphology (data not shown) or growthwere observed
betweenWT and CTCF lines (Fig. 5A). The physical state of the
HPV genomes was determined by Southern blotting and qPCR.
Both WT and CTCF HPV18 lines were shown to contain epi-
somal HPV genomes at a similar copy number of approximately
200 copies/cell (Fig. 5B and C). Importantly, we demonstrated a
10-fold reduction in CTCF binding to CTCF HPV18 genomes
compared to the level for the WT (Fig. 5D).
Loss of CTCF binding induces a hyperproliferative pheno-
type in organotypic culture. To assess the biological function of
CTCF recruitment to the HPV18 genome in differentiating epi-
thelium, WT and CTCF HPV18 HFK lines were grown in orga-
notypic raft culture. Formaldehyde-fixed rafts were paraffin em-
bedded and sectioned. Sections were stained with hematoxylin
and eosin to assessmorphology (Fig. 6A). As previously described,
the WTHPV18 genome-containing rafts were increased in thick-
ness, and mitotic cells were visible in the lower and upper su-
prabasal layers of the rafts compared to rafts derived from HFKs
that did not contain HPV18 genomes (13). This phenotype was
enhanced in CTCF HPV18 rafts, which were consistently
thicker, indicating increased cellular proliferation. Alongside
these experiments, viral genome amplification was assessed by
chromogenic in situ hybridization (C-ISH). No consistent differ-
ences were observed in the number of cells with amplified HPV
genomes between WT and CTCF HPV18 rafts, demonstrating
that CTCF recruitment has a minimal role in viral genome
amplification (Fig. 6A and B).
FIG 2 Summary of in silico-predicted CTCF binding sites and in vitro analysis. Graphical representations of the HPV16, HPV18, HPV31, HPV11, and
HPV6b genomes are shown. ORFs are indicated on each genome (light gray). Predicted CTCF binding sites are represented by the black bars. The hashed
bars on the periphery of each genome highlight fragments tested by EMSA, and the dark gray bars on each genome indicate those fragments that bound
CTCF in vitro.
Paris et al.
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Increased S phase and G2 entry is caused by loss of CTCF
binding. The increase in hyperproliferation in CTCF HPV18
rafts could be explained either by delayed epithelial differentiation
or by increased S phase entry. To assess molecular differentiation,
raft sections were stained for markers of undifferentiated kerati-
nocytes (keratin 5), early differentiation (keratin 1), and late dif-
ferentiation (loricrin) alongside E1^E4, a marker of the produc-
tive phase of the HPV life cycle (Fig. 6C). Expression patterns of
keratin 5, keratin 1, and loricrin were similar between WT and
CTCF HPV18 organotypic cultures, with keratin 5 confined to
the basal and parabasal layers with some nonspecific staining vis-
ible in the cornified layer of the epithelium; keratin 1 and loricrin
were expressed in the suprabasal and upper layers, respectively.
However, keratin 1 and loricrin staining highlighted differences in
the morphology of cells in the suprabasal and upper layers of the
epithelium; rather than a flattening of these cells in the upper
layers, as can be seen in theWTHPV18 sections, the cells appeared
to maintain a rounded morphology. This difference in morphol-
ogy also is visible in the hematoxylin- and eosin-stained sections
shown in Fig. 6A.
BrdU incorporation was used to assess cell cycle entry and cel-
lular DNA replication. BrdU-positive cells were confined to the
basal layer in rafts derived from untransfected donor keratino-
cytes (Fig. 7A). Increased S phase entry was observed in the basal
and suprabasal layers of the WT HPV18 rafts, as previously re-
ported (36). In contrast, CTCF HPV18 rafts displayed a signifi-
cant decrease in S phase entry in the basal layer compared to that
of theWT. A decrease in the percentage of BrdU-positive cells was
observed in the lower suprabasal layers of CTCF HPV18 rafts
compared to that of the WT, although this did not reach signifi-
FIG 3 Association of CTCF with HPV genomes. Chromatin extracted from HPV16-positive W12 cells (A) and HPV18-positive HFKs (B) was immunopre-
cipitated with control antibody (rabbit IgG for W12 and FLAGM2 antibody for HPV18 HFKs) or CTCF-specific antibody. Coprecipitating DNA was analyzed
by qPCR. The x axes indicate the position in the HPV genome amplified, and each data point represents the central point in each amplicon. A graphical
representation of the HPV genome is shown above each data set, which has been linearized for ease of presentation (Enh, enhancer; Ep, early promoter). The
CTCF binding sites verified by EMSA (Fig. 1 and Table 2) are indicated (dark gray ovals). Binding efficiency was normalized to negative-control antibody using
the CT method. The data represent the means and standard errors from three independent repeats.
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cance. In contrast, a significant increase in the percentage of
BrdU-positive cells was observed in the upper suprabasal layers of
the CTCF HPV18 rafts (Fig. 7B).
Raft sections also were stained for cyclin B1 and P-H3 (Ser10)
asmarkers of G2 andmitotic entry, respectively (Fig. 7C and E). In
agreementwith the BrdU incorporation analysis (Fig. 7A andB), a
decrease in cells positive for cytoplasmic cyclin B1was observed in
the basal layer of CTCF HPV18 lines compared to that of the
WT. No significant difference was observed in the lower su-
prabasal compartment, but an increase in cytoplasmic cyclin B1 in
the upper suprabasal layers was noted (Fig. 7C andD). In contrast,
there was no difference in the number of cells positive for P-H3 in
WT and CTCF HPV18 structures (Fig. 7E and F). Taken to-
gether, these data indicate that there is an increase in cell cycle
entry with a corresponding increase in S and G2 phases in the
upper layers of the epithelium of CTCF HPV18 cells. The cells
appear to arrest at G2 phase as an increase in mitotic entry is not
observed. These data provide evidence that loss of CTCF binding
within the HPV18 E2 ORF leads to a delay in cell cycle exit and an
enhanced hyperproliferative phenotype.
CTCF binding within the E2 ORF controls the expression of
viral oncoproteins E6 and E7. The increased cell cycle entry and
hyperproliferation observed in the organotypic raft cultures de-
rived fromHFK linesmaintainingCTCFHPV18 genomes could
be due to an increase in the expression of E6 and E7 viral onco-
proteins. Detection of these proteins by immunostaining cur-
rently is not possible; therefore, raft sections were stained with
surrogate markers, p53 as a marker for E6 expression and pRb
family member p130 for E7 expression (8, 41). Cells stained pos-
itive for p53 inWTHPV18 raft sectionswere apparent throughout
the epithelia as previously reported (42), albeit at a noticeably
decreased level compared to that of rafts derived from untrans-
fected HFKs (Fig. 8A). In contrast, p53-positive cells were unde-
tectable in rafts derived fromCTCFHPV18 lines (Fig. 8A andB).
This observation is consistent with an increase in E6 protein levels
in CTCF HPV18 compared to that of the WT, resulting in a
decrease in detectable p53 protein. Similarly, immunostaining
with p130-specific antibodies revealed significant differences be-
tweenWT andCTCFHPV18 rafts (Fig. 8C and D). In wild-type
HPV18 rafts, p130-positive cells were confined to the upper layers,
as previously shown (42) and in contrast to HPV-negative HFK
raft sections, where cells stained positive for p130 in the parabasal
and lower and upper suprabasal layers. However, immunostain-
ing of p130 in theCTCFHPV18 raft sections revealed an almost
complete loss of p130-positive cells in the upper layers, suggesting
increased and prolonged expression of E7 protein in the CTCF
HPV18 rafts compared to that of the WT.
Since p53 andp130 expression only provide an indication of E6
and E7 activity, we also quantified expression of early transcripts
that have the potential to encode E6 and E7 by reverse transcrip-
tase PCR (RT-PCR). As expected, the relative abundance of un-
spliced E6E7 transcripts in CTCF HPV18 raft cultures was sig-
nificantly increased compared to that of the WT (Fig. 9A and B).
E6E7 transcript levels also weremeasured by qPCRusing the same
primer set as that described above and compared to the human
RPLPO gene (Life Technologies). A ratio of E6E7 transcript to
RPLPO transcript in HPV18 wild-type and CTCF rafts was cal-
culated using the Livak 2CTmethod.Donor 1was shown to have
a 21.19-fold increase (
10.48-fold standard errors [SE]) and do-
nor 2 had a 44.08-fold increase (
26.95-fold SE) in E6E7 tran-
script in the HPV18CTCF rafts compared to wild-type levels. In
addition, Western blot analysis of protein extracts from raft cul-
FIG 4 Mutation of the CTCF binding site at position 2989 in HPV18. (A) Wild-type HPV18 sequence between nucleotides 2976 and 3035 showing the
primary CTCF binding site starting at nucleotide 2989 and the secondary binding site in lowercase. The amino acid sequence of E2 protein in this region
is shown below the DNA sequence. The 3 conservative nucleotide substitutions created in the mutated CTCF HPV18 genome (C¡T2993, G¡A3002, and
T¡C3020) are indicated (*). (B) Abrogation of CTCF binding was assessed by EMSA. The CTCF binding region of the c-Myc locus (positive control), a
region of the BPV-1 genome that does not contain CTCF binding sites (negative control), and the CTCF binding regions in the E2 ORF in wild-type and
CTCF mutant genomes were amplified and FAM labeled by PCR. DNA fragments were mixed with binding buffer (DNA) alone or with in vitro-
translated luciferase () or CTCF (	), and complexes were separated on a native acrylamide gel. In agreement with data presented in Table 2, CTCF
bound strongly to the wild-type HPV18 (18_3) fragment compared to the positive control; however, binding of CTCF to theCTCFmutant fragment was
severely disrupted.
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tures harvested at day 14 demonstrated a clear increase in E6 and
E7 protein levels (Fig. 9C), which was consistent in both donor
lines.
The increase in E6E7 unspliced transcript could be due to an
increase in the activity of the early promoter. HPV-encoded E2
protein is known to repress the activity of this promoter, and
changes in E2 expression could affect early promoter activity (43–
45). To determine whether the expression level of E2 protein was
affected by the mutations introduced into the E2 ORF in the
CTCF HPV18 genome, E2 protein levels in raft lysates were de-
tected by Western blotting, and no changes were observed (Fig.
9C). Furthermore, immunostaining of sections showed E2 stain-
ing in the intermediate and upper layers of the WT raft cultures,
with obvious cytoplasmic and nuclear localization. As previously
described, E2 staining was not detected in the basal and lower
suprabasal cells, presumably because E2 protein levels are below
the level of detection (9). No staining was detected in the HPV-
negative HFK raft control, demonstrating specificity of the anti-
body. An equal intensity of E2-specific signal was observed in the
upper layers of wild-type and CTCF HPV18 rafts, although a
delay in E2 expression was consistently observed in CTCF
HPV18 rafts compared to that of the WT. This presumably is due
to an expansion of the E2-negative midlayers of the epithelium
caused by increased E6 and E7 expression (Fig. 9D). Together,
these data confirm that steady-state E2 levels in the raft cultures
were not affected by the mutations introduced into the HPV18
FIG 5 Creation of HPV18 wild-type and CTCF mutant human foreskin keratinocyte lines. HFKs established from two independent donors were transfected
withWT orCTCFHPV18 genomes. (A) Analysis of growth kinetics using a CCK-8metabolic assay. Cells were seeded at equal density at day 0, and the growth
of each line was measured at days 1, 3, 5, and 7. The data show the means and standard errors from two independent experiments performed in triplicate. (B)
HPV18 genome copy number was determined by qPCR analysis of DpnI-digested DNA extracted from each line using the Pfaffl comparative CT method and
normalized against the TLR2 locus (37). Data show the means and standard errors from three independent repeats (donor 1, P  0.9; donor 2, P  0.2). (C)
HPV18 genome status was determined by Southern blotting from extracted DNA from donor 1 and donor 2 transfected with either wild-type (WT) or CTCF
mutant (C)HPV18 genomes (OC, open circle; L, linear; SC, supercoiled). DNAwas linearized with EcoRI, producing a single band of similar intensity running
at approximately 8 kbp, demonstrating themaintenance of viral episomes at a similar copy number in each line. Digestionwith BglII showsminimalmultimeric/
integrated HPV genomes in all lines. (D) Abrogation of CTCF binding by mutation of the CTCF binding site was determined by ChIP. Chromatin was either
immunoprecipitated with FLAG (negative control) or CTCF antibody, and the percentage of boundHPV18 genomewas determined by qPCRwith primers that
flank the CTCF binding site at position 2989. A significant decrease in CTCF binding was observed inCTCFHPV18 compared to that of the wild type (**, P
0.01). The data shown represent the means and standard errors from two independent repeats performed in duplicate (donor 1; donor 2 showed a similar
decrease in CTCF binding).
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genome. Collectively, these data demonstrate that CTCF recruit-
ment to the conserved site within the E2 ORF is important in the
regulation of viral oncoprotein expression in the differentiation-
dependent life cycle through a mechanism that does not involve
aberrant E2 protein expression.
CTCF controls RNA splicing of early viral transcripts. A di-
verse range of early transcripts is expressed from theHPV genome
as a result of numerous alternative splicing events (14, 15). Alter-
ations in the splicing events that are important in early gene ex-
pression in HPV infections could have a dramatic effect on the
expression of early proteins and their truncated forms (E6*I,
E6*II, and E6*III) (14). Given its previously described role in the
control of RNA splicing (21), CTCF binding to the E2 ORF could
affect splicing of the early transcripts and viral oncoprotein
expression. To test this hypothesis, RNA was extracted from
raft cultures harvested at day 14 and from early transcripts
amplified by RT-PCR with primer pairs that were designed
previously to identify the specific splicing events that occur
within the early region of the HPV18 genome (14, 15). Ampli-
fication with a 5= primer that anneals at nucleotide 121, up-
FIG 6 Morphology and differentiation of HPV18 CTCF organotypic raft cultures. (A, upper) Organotypic raft cultures of HFK, WT HPV18, and
CTCF HPV18 lines were fixed at day 14, and sections were stained with hematoxylin and eosin to assess morphology (upper). (Lower) Sections were
stained by C-ISH to qualitatively assess viral genome amplification. Brown nuclear staining is present in cells with amplified HPV18 genomes. Scale bar,
10 m. (B) The number of cells positive for C-ISH in wild-type and CTCF HPV18 sections was counted in 10 fields of vision from sections of three
independent raft cultures from each line (n  30). The data are shown as means and standard errors. (C) Sections were stained with antibodies specific
for keratin 5 (green; upper), keratin 1 (green; middle), or loricrin (red; lower). Sections were counterstained with Hoechst to highlight the nuclei (blue)
and E1^E4 antibody to highlight productive areas of each section (red in upper andmiddle panels [rabbit antibody r424], green in the lower panel [mouse
antibody 1D11]). Scale bar, 10 m.
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stream of the first splice donor site at nucleotide 233, and 3=
primer that anneals at nucleotide 3517, downstream of the five
splice acceptor sites in the early region of HPV18 at nucleotides
416, 2779, 3434, 3465, and 3506 (14, 15), was used to detect any
major splicing events that occur in the early region of the
HPV18 genome. Amplification of RNA from WT HPV18 rafts
resulted in two major products, with some minor products
visible (Fig. 10A). As previously described (14), the two major
products of 708 and 195 bp were identified by sequencing and
shown to be spliced at 233^416 and 929^3434 and at
233^3434, respectively (Fig. 10B). Both of these products were
consistently expressed in five raft cultures from each individual
donor line of WT HPV18 HFKs. Of note, the 195-bp product,
spliced between nucleotides 233 and 3434, was significantly
reduced in and, in some cases, absent from the CTCF HPV18
raft cultures (Fig. 10A and C). This is in contrast to the increase
in unspliced transcript in the CTCF HPV18 rafts (Fig. 9A and
B). Therefore, a significant reduction in production of the
short mRNA species (233^3434 spliced product) could result
in the observed increase in unspliced E6E7 transcripts. Further
analysis of viral transcripts revealed that splicing events at nu-
cleotides 233^416 and 929^3434 were not altered by the loss of
CTCF binding (Table 3). These experiments demonstrate that
the loss of CTCF binding at position 2989 within the HPV18
genome results in a significant alteration in splice site usage,
with the specific loss of 233^3434 spliced products in the early
transcripts expressed.
DISCUSSION
This study aimed to identify CTCF binding sites within the ge-
nomes of various HPV types and to understand the function of
CTCF in the virus life cycle. In silico predictions were used to
identify potential CTCF binding sites, a high frequency of which
bound CTCF in vitro. The relative position of many of the CTCF
binding sites is conserved. A cluster of CTCF binding sites was
identified in the late gene region of all of theHPV types tested, and
binding within the E2 ORF appears to be conserved in the high-
risk types, indicating that recruitment of CTCF to this region is
related to the ability of the virus to induce cellular transformation.
This suggests that the recruitment of CTCF to these regionswas an
early evolutionary event and that CTCF is important for the virus
life cycle. Furthermore, the frequency of CTCF binding sites
within the genomes of the HPV types analyzed in this study show
an enrichment of sites compared to the frequency of binding sites
within the human genome (20).
In contrast to the binding of CTCF within the E2 ORF in
HPV16 and HPV18, CTCF recruitment within the late gene re-
gion was not detected in genome-containing cells. The conserva-
tion of the CTCF binding site cluster in the late gene region sug-
gests that recruitment of CTCF to the late region is important for
a defined point in the HPV life cycle. During submission of the
manuscript, we became aware of a study by Metha et al. in which
CTCF was shown to associate with the sites within the L2 gene of
the late gene region of HPV31. Loss of CTCF binding to the
HPV31 L2 gene appears to prevent viral genome amplification (K.
Metha, V. Gunasekharan, A. Satsuka, and L. Laimins, submitted
for publication). However, our data show that CTCF does not
bind within the late gene region in HPV16 and HPV18 in cells
grown in monolayer culture. It is possible that CTCF recruitment
to this region is promoted by cellular differentiation, and this is
important for capsid protein expression or viral genome amplifi-
cation. Differentiation-induced loss of CpG methylation in the
late region of episomal HPV16 genomes has been reported (46).
CpG methylation can negatively regulate CTCF binding (47),
making this method of regulation of CTCF recruitment to the late
gene region of the HPV genome in differentiating epithelium a
plausible hypothesis.
Several host cell proteins are recruited to the HPV genome
to regulate transcriptional control. The binding of host cell
transcription factors to sequences within the URR to control
early gene transcription has been well characterized. Tran-
scriptional regulators, such as AP1 (48), SP1 (49), TFIID (50),
TBP (51), NF1, and Oct-1 (52), have defined binding sites
within the URR of all HPV types analyzed. Many other tran-
scriptional regulators are recruited by association with the E2
protein, including Brd4 (53), TaxBP1 (54), p300, and CBP
(55). In contrast, very few host or viral proteins have been
shown to bind specifically to the HPV genome outside the
URR, although evidence of C/EBP, Oct-1, and YY1 binding to
sequences upstream of the late promoter within the E7 ORF in
HPV18 has been reported (56–58). The recruitment of CTCF
to a binding site that exists within the E2 ORF is, to our knowl-
edge, the first description of a cellular factor recruited to a
specific binding site outside the URR or late promoter regions
to control viral gene expression.
Mutation of the CTCF binding site within the E2 ORF of
HPV18 has highlighted an important function of CTCF in the
HPV life cycle. Growth of cells in organotypic raft culture was
affected by abrogation of CTCF binding, and we noted a signifi-
cant increase in cellular proliferation coupled with enhanced E6
and E7 protein expression. These data provide evidence that loss
of CTCF binding within the E2 ORF enhances E6 and E7 expres-
sion in differentiating cells, prolonging the proliferative potential
of cells in the middle and upper layers of the stratified epithelium.
It is interesting that although we observed an increase in cell cycle
entry in the CTCF HPV18 raft cultures, we did not observe an
FIG 7 Cell cycle entry in wild-type andCTCFmutant HPV18 genome-containing organotypic raft sections. Sections were stained with anti-BrdU (green) (A),
cyclin B1 (red) (C), and phospho-histone H3 (green) (E). DNA was stained with Hoechst to highlight the nuclei (blue). Representative sections of WT and
CTCF HPV18 genome-containing HFK rafts are shown. The white arrows indicate the basal layer, and the lower suprabasal/upper suprabasal boundary is
highlighted with a dashed line. Scale bar, 10 m. The percentage of cells stained positive for nuclear BrdU (B), cytoplasmic cyclin B1 (D), and phospho-histone
H3 (F) in the basal, lower suprabasal (parabasal and lower spinous), and upper suprabasal (upper spinous and granular) layers of 15 fields of view of 3
independent rafts (n 45) from each donor was determined. The data represent the means and standard errors. (B) A significant reduction in BrdU incorpo-
ration is observed in the basal layer ofCTCFHPV18 lines (***,P 0.002), a small reduction is observed in the lower suprabasal compartment that did not reach
significance (P 0.07), and a significant increase in BrdU incorporation is observed in the upper suprabasal layers of the CTCF HPV18 rafts compared to the
wild type (***, P 0.0002). (D) A significant reduction in cyclin B1-positive cells is observed in the basal layer ofCTCFHPV18 lines (*, P 0.04), no difference
is observed in the suprabasal compartment, and a significant increase in cyclin B1-positive cells is observed in the upper layers of the CTCF HPV18 rafts
compared to those of the wild type (***, P 0.00006). (F) No significant differences in P-H3-positive cells were observed.
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increase in mitotic entry. One possible explanation for this is that
the raft cultures were harvested at 14 days when the epithelia were
fully differentiated. It is possible that an increase inmitosis occurs
as the epithelium is developing and that in a fully differentiated
epithelium, the cells are more likely to arrest in G2 than progress
throughmitosis. Importantly, there were no discernible effects on
the overall expression of E2, although expansion of the midlayers
of the epithelium resulted in an apparent delay in E2 expression.
In addition, viral genome replication and amplification were un-
affected, suggesting that E1 protein levels were unaffected. This
suggests that HPV18 and perhaps other oncogenic HPV types
have evolved to bind CTCF in this region to regulate balanced and
controlled E6 and E7 expression in the context of a productive
infection. Interestingly, CTCF does not appear to bind to the site
within the E2ORF in integrated sequences inHeLa cells (59), even
though three copies of the binding site exist (60). It is possible that
FIG 8 Analysis of p53 and p130 degradation in wild-type and CTCF HPV18 organotypic raft sections. (A) Sections were stained with p53-specific antibody
(green), andDNAwas stainedwithHoechst (blue). The white arrows indicate the basal layer, and the lower suprabasal/upper suprabasal boundary is highlighted
with a dashed line. Scale bar, 5m. (B) The percentage of cells positive for nuclear p53 staining in the basal, lower suprabasal (parabasal and lower spinous), and
upper suprabasal (upper spinous and granular) layers of 15 fields of view of 3 independent rafts (n 45) from each donor was determined. The data represent
the means and standard errors. A significant reduction in p53-positive cells is observed in all layers of rafts derived from the CTCF HPV18 lines (***, P 
0.0005). (C) Sections were stained with p130-specific antibody (green), andDNAwas stained withHoechst (blue). The white arrows indicate the basal layer, and
the lower suprabasal/upper suprabasal boundary is highlighted with a dashed line. Scale bar, 5m. (D) The percentage of cells positive for nuclear p130 staining
in the basal, lower suprabasal (parabasal and lower spinous), and upper suprabasal (upper spinous and granular) layers of 15 fields of view of 3 independent rafts
(n 45) fromeachdonorwas determined. The data represent themeans and standard errors. A significant reduction in p130-positive cells is observed in all layers
of rafts derived from the CTCF HPV18 lines (***, P 0.001).
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CpGmethylation prevents CTCF binding to this site inHeLa cells,
as previously reported (47, 61), and it is tempting to speculate that
the apparent loss of CTCF binding in integrated HPV18 genomes
inHeLa cells contributes to the high E6 and E7 expression in these
cells.
It should be noted that CTCF binding sites have been iden-
tified within the genomes of large DNA viruses, such as Ep-
stein-Barr virus (EBV) and Kaposi’s sarcoma-associated her-
pesvirus (KSHV). Mutation of sites to prevent CTCF binding has
demonstrated that CTCF determines latency in these viruses by
blocking epigenetic silencing of latency-associated promoter ele-
ments and mediating long-range interactions within the viral ge-
nome (62–68). This, in part, is thought to be through CTCF-
dependent regulation of nucleosome organization and control of
FIG 9 Analysis of unspliced E6E7 transcript and protein expression in organotypic raft culture. RNA extracted from 14-day-old raft cultures was converted to
cDNA and amplified between nucleotides 121 and 295. The products of this PCR are unspliced early transcripts (14). Amplification of GADPH from the same
samples is shown as a loading control. Products were separated by electrophoresis (A) and quantified by densitometry using ImageJ (B). An increase in E6E7
transcript was observed in CTCF HPV18 lines established from individual donors (*, P  0.03 for donor 1 and donor 2). (C) Proteins extracted from raft
cultures were analyzed by Western blotting. Fold increase in virus protein expression compared to the wild type (normalized to GAPDH protein) is indicated
below each membrane section. The images shown are representative of three technical repeats of lysates extracted from two independent donor lines. (D) E2
protein localization (red in themerged image; DNA is blue) in raft sections of HFK, wild-type, andCTCFHPV18 genome-containing lines. The images shown
are representative of two independent raft cultures of each individual donor line. Scale bar, 10 m.
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RNA polymerase II recruitment to the latency control region (69,
70). Whether CTCF binding within the E2 ORF of the HPV ge-
nome directly controls E6E7 transcript production through sim-
ilar mechanisms currently is being explored.
CTCF binding within the host genome controls cotranscrip-
tional alternative splicing events by creating a roadblock to pro-
cessing RNA polymerase II and promoting inclusion of weak up-
stream exons (21). Therefore, we analyzed splicing events that
occur in the HPV early transcripts in differentiating epithelium
and demonstrated a significant increase in the unspliced early
transcript that encodes the E6 and E7 oncoproteins. In addition,
the transcript spliced directly at 233^3434 was markedly reduced
in CTCF HPV18 rafts, while the abundance of all other spliced
products was unchanged. The transcript spliced at 233^3434
could be used as a template for translation of E6*II and E5 (14).
Multiple transcripts that are abundantly and equally expressed in
ourWTandCTCF rafts potentially encode E5 protein,making it
unlikely that E5 expression is affected by loss of CTCF binding.
Whether the loss of E6*II expression contributes to the phenotype
observed in our mutant HPV18 HFK rafts remains to be deter-
mined.
Our data suggest that CTCF recruitment to the E2 ORF bind-
ing site is a controlmechanism for the expression of unspliced and
alternatively spliced early transcripts in the HPV life cycle. It is
interesting that the currentmodel of CTCF-mediated splicing reg-
ulation predicts that DNA-bound CTCF pauses RNA polymerase
II progression and promotes the inclusion of weak upstream ex-
ons by allowing the splicing machinery more time to process the
nascent RNA strand (21). Our data support a role for CTCF in
directing splicing events but suggests that the function of CTCF
in this process is more complex than the current model predicts.
In our physiologically relevant model system, loss of CTCF bind-
ing results in both increased levels of unspliced transcripts and a
complex alteration of splice site usage upstream of the CTCF
FIG 10 Loss of CTCF binding causes aberrant splicing of early transcripts. RNA extracted from 14-day-old raft cultures was converted to cDNA and amplified
between nucleotides 121 and 3517. (A) The products were gel purified and sequenced. (B) Graphical representation of the identified products. (C) The 195-bp
productwas quantified using ImageJ, and relative amountswere normalized towild-type levels for each donor. The data shown represent themeans and standard
errors of RNA extracted from 3 independent raft cultures from each donor (donor 1, P 0.0008 [***]; donor 2, P 0.0095 [***]).
TABLE 3 Analysis of splicing events in early transcripts produced in organotypic raft culturea
Primers Splice(s)
Product
size (bp)
Fold change
Inferred ORFsDonor 1 P Donor 2 P
121/295 Unspliced Early 175 1.65
 0.27b 0.03 2.47
 0.57 0.03 E6, E7
E1F1/E4R 929^3434 190 1.049
 0.086 0.58 1.058
 0.26 0.83 E1^E4, E5
121/3517 233^416, 929^3434 708 1.03
 0.1 0.75 0.98
 0.008 0.07 E6*I, E7, E1^E4, E5
121/3517 233^3434 195 0.37
 0.087c 0.0008 0.59
 0.11 0.009 E6*II, E5
a RNA extracted from 14-day-old raft cultures was converted to cDNA and amplified with the indicated primer pairs. The fold change in transcript level compared to that of wild-
type HPV18 rafts is shown as the means and standard errors from three independent repeats. Significance (P) was calculated using Student’s t test.
b Significant increase in expression levels.
c Significant decrease in expression levels compared to wild type.
CTCF Controls HPV Early Gene Expression
May 2015 Volume 89 Number 9 jvi.asm.org 4783Journal of Virology
 o
n
 N
ovem
ber 24, 2015 by M
RC LAB O
F M
O
LECULAR BIO
LO
G
Y
http://jvi.asm.org/
D
ow
nloaded from
 
binding site. Further study of CTCF in the regulation of RNA
processing likely will highlight novel functions of CTCF in gene
expression regulation.
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